News

Filter

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Ablynx gets 2 million-euro milestone from Boehringer Ingelheim Alzheimer’s collaboration; latter to unveil positive data on cancer drug

24-05-2010

German independent drug major Boehringer Ingelheim has selected a nanobody lead candidate for further…

AblynxBiotechnologyBoehringer IngelheimLicensingNeurologicalOncologyPharmaceuticalResearch

Back to top